Keystone eSymposia Logo

Joint meeting with HIV Vaccines

HIV Pathogenesis and Cure

June 1-4, 2021 | 9:00AM EDT | 1:00PM UTC | 3:00PM CEST*
*Program is in development and subject to change


The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.

 Free Access to On Demand Content to Scientists from Low-and Middle-Income Countries

Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.

Apply Here

Human Immunodeficiency Virus type 1 (HIV) is the cause of a global pandemic that has a very high mortality rate, with an estimated 35 million deaths to date. In addition, another 37 million people are currently living with HIV infection and will likely succumb from acquired immune deficiency syndrome (AIDS) without lifelong antiretroviral therapy (ART). Optimal ART can halt viral replication, thereby preventing disease progression and allowing immune reconstitution. However, ART is not curative due the persistence of a latent form of the virus. This latent form is the major barrier to cure and the subject of an intense international research effort. Along with efforts to develop an HIV vaccine, targeting the HIV latent reservoir is a major priority for AIDS research. Achieving a better understanding of the basic biology of HIV infection is likely to be essential to HIV cure efforts. 

This conference will bring together scientists studying basic aspects of HIV virology as well as investigators working directly on the cure problem. Immune-based strategies to eliminate infected cells are an important component of many cure strategies, providing a logical connection to hold the joint conference on HIV Vaccines. This pairing will provide a unique opportunity to bring together basic and translational immunologists and virologists to consider the challenging goal of curing HIV infection. In addition to joint sessions focusing on exciting new developments in the study of antibody and T cell responses to HIV and novel technologies that will aid future studies of HIV biology, sessions also include basic mechanisms of HIV integration and transcriptional control, strategies for reversing latency and eliminating infected cells, and trials of novel cure strategies in animal models and in patients on ART. The goal of this conference is to bring together an amalgamation of basic and applied scientists working on functional cures and eradication of HIV in an effort to not only better understand HIV treatment strategies but also the emerging technologies and approaches that will lead to the eventual eradication of HIV from infected individuals.

Apply Here for Free On Demand Access


Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD


Abstract Submission
‣ For Short Talk Consideration: Passed
‣ For ePoster Presentation: Passed
Final ePoster / SciTalk Submission: Passed
Financial Aid Application: Passed

*Abstract submission is required in order to submit an ePoster and/or Scitalk


Program Details

Keynote Speakers


M. Juliana McElrath
Fred Hutchinson Cancer Research Center


Bruce D. Walker
Ragon Institute of MGH, MIT and Harvard

Speaking at this eSymposia

Julie Ake

Walter Reed Army Institute of Research, USA

Petronela Ancuta

Centre de Recherche de l'Universite de Montreal, Canada

Dan H. Barouch

Beth Israel Deaconess Medical Center, USA

Maria J. Buzon

Vall d´Hebron Research Institute, VHIR, Spain

Paula M. Cannon

University of Southern California, Keck School of Medicine, USA

Angela Ciuffi

Institute of Microbiology - CHUV/UNIL, Switzerland

Bryan R. Cullen

Duke University Medical Center, USA

Mark M. Davis

Stanford University School of Medicine, USA

Steven G. Deeks

University of California, San Francisco, USA

Barbara K. Felber

NCI, National Institutes of Health, USA

Guillaume J. Filion

Centre of Genomic Regulation, Spain

Beatrice H. Hahn

University of Pennsylvania, USA

Reuben S. Harris

University of Minnesota, USA

Brad Jones

Weill Cornell Medicine, USA

Frank Kirchhoff

University of Ulm, Germany

Sharon R. Lewin

University of Melbourne, Australia

Marina Lusic

University Clinic Heidelberg, Germany

M. Juliana McElrath

Fred Hutchinson Cancer Research Center, USA

Beatriz Mothe

IrsiCaixa AIDS Research Institute-HIVACAT, Spain

Afam Okoye

Oregon Health & Science University , USA

Melanie M. Ott

Gladstone Institutes, USA

Rafick Sekaly

Emory University, USA

Devi SenGupta

Gilead Sciences, Inc., USA

Liang Shan

Washington University in St. Louis, USA

Robert F. Siliciano

Johns Hopkins University School of Medicine, USA

Carine M. Van Lint

University of Brussels, Belgium

Bruce D. Walker

Ragon Institute of MGH, MIT and Harvard, USA

Xu Yu

Massachusetts General Hospital, USA

Jerome A. Zack

University of California, Los Angeles, USA





Additional Support




Funding for this conference was made possible (in part) by Grant No. [GRANT NUMBER - UPDATE] from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Media-in-Kind Support









The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.


This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community.  Here, Debbie Johnson, our CEO, explains how we're going to do that.

Donate to Keystone Symposia

Donate to Keystone Symposia